VOYA Investment Management
ELVN icon

VOYA Investment Management’s Enliven Therapeutics ELVN Stock Holding History

VOYA Investment Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.78M Buy
74,453
+59,962
+414% +$2.55M ﹤0.01% 983
2026
Q1 		$568K Buy
+14,491
New +$401K ﹤0.01% 1671
2025
Q1 		– Sell
-10,702
Closed -$241K – 2666
2024
Q4 		$241K Sell
10,702
-945
-8% -$24.5K ﹤0.01% 2312
2024
Q3 		$297K Sell
11,647
-186
-2% -$4.31K ﹤0.01% 2264
2024
Q2 		$277K Buy
+11,833
New +$249K ﹤0.01% 2292

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VOYA Investment Management's ELVN Position: Q2 2026 in Review

VOYA Investment Management increased its Enliven Therapeutics (ELVN) stake by 414% in Q2 2026, buying an estimated $2.55M and bringing the position to 74,453 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #983.

VOYA Investment Management first reported a position in ELVN in Q2 2024 and has held it in 5 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • VOYA Investment Management held 74,453 shares of Enliven Therapeutics worth $3.78M as of Q2 2026.
  • VOYA Investment Management bought 59,962 Enliven Therapeutics shares in Q2 2026, an estimated $2.55M.
  • Enliven Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #983 holding.
  • VOYA Investment Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.